Assessing the Potential Implications of New Data in Chronic Spontaneous Urticaria

Program Overview

Treatment options for chronic spontaneous urticaria (CSU) are limited, with up to 40% of patients not responding to first-line therapy and a third not responding to second-line treatment. Moreover, many will continue to remain refractory in the third-line setting, highlighting the need for newer therapeutic agents. This Clinical Transfers^® activity brings to you the latest data on emerging therapies from this year’s annual meeting of allergists and immunologists in Phoenix, AZ.

Credit Expired

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
Assess current safety and efficacy data on emerging therapies for the treatment of CSU

Activity Faculty

Jonathan A. Bernstein, MD

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Featured RMEI CE Activities – Earn CE Credit(s)

A Violent Graft in a Vulnerable Host: The Future of aGvHD Management: A Care Team Forum®

1.5 CE Credit(s)

Rapid Recognition and Management of T-Cell Therapy-Related Toxicities in B-Cell Lymphomas: Crucial Updates for the Emergency Department

1.0 CE Credit(s)

Beyond the Guidelines for CMV: Clinical Perspectives on Challenging Cases Post-Transplant: A Clinical Forum®